Litigation Details for Eli Lilly and Company v. Cipla Ltd. (D. Del. 2026)

Eli Lilly and Company v. Cipla Ltd. (D. Del. 2026)

Docket		Date Filed	2026-06-12
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	CIPLA LTD.
Patents	7,855,211
Link to Docket	External link to docket

Details for Eli Lilly and Company v. Cipla Ltd. (D. Del. 2026)

Date Filed	Document No.	Description	Snippet	Link To Document
2026-06-12				External link to document

Last updated: July 16, 2026

ecutive summary
No litigation summary can be produced for “Eli Lilly and Company v. Cipla Ltd., 1:26-cv-00691” because the underlying case docket, asserted patents (and claims), forum/venue details, and order history are not provided. Without those case-specific facts, any summary would be non-actionable.

Litigation summary and analysis for Eli Lilly and Company v. Cipla Ltd.|1:26-cv-00691

Key Takeaways

• The requested case-specific litigation summary cannot be generated from the identifier alone.

FAQs

1. What determines whether a generic launch would trigger a Paragraph IV filing in Hatch-Waxman cases?
2. How do courts typically construe asserted claims in ANDA patent infringement actions?
3. What are the most common outcomes of early motions to dismiss in Hatch-Waxman litigation?
4. How do district court Markman rulings affect settlement probability in generic patent disputes?
5. What information in a docket is most predictive of an imminent trial date?

References